Novartis

Novartis Working Capital

The Working Capital of Novartis (NOVN.SW) as of Nov 3, 2026 is -2.92 B USD. In the previous year, Working Capital was -4.32 B USD — a change of -32.25% (higher).

Working Capital

-2.92 BUSD

YoY

-32.25%

Last updated:

Working Capital of Novartis is 2025 -2.92 B USD. Working Capital of Novartis was 2024 -4.32 B USD. It decreases by -32.25% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Novartis Stock analysis

What does Novartis do? Novartis AG is a globally active company operating in the pharmaceutical, ophthalmology, and generics manufacturing sectors. The company, headquartered in Basel, Switzerland, was founded in 1996 and originated from a merger between Ciba-Geigy and Sandoz. Novartis AG is now a leading company worldwide in the research, development, production, and marketing of pharmaceuticals and other health products. Novartis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novartis stock

Working Capital of Novartis is -2.92 B USD in 2025.

Working Capital of Novartis changed from -4.32 B USD to -2.92 B USD, representing a -32.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Working Capital Novartis since 2006 – with annual values, charts, and detailed analysis.

Working capital is the difference between current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations.

Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Working Capital's Novartis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Novartis

All Key Metrics — Novartis